Gilead Sciences GILD

Nasdaq · Biological Products, (No Diagnostic Substances) · $216.3B

$167.57−3.96%Nov 5 close · Databento

Every report since 2023 →

🔒 Click to interact · scroll moves the page

GILD Wire Story Reactions & EOD Technical StudyDaily closes (Databento EOD) pinned with every AlgoThesis Wire story (dot colour = next trading day close) and SEC filing

Nov 5, 2026CLOSE $167.571D −3.96%3M +25.94%SMA20 $159.31SMA50 $152.68RSI(14) 61.3

167.57

RSI (14, Wilder EOD) · 70 Overbought / 30 OversoldRSI 61.3

Data provided by Databento (end of day). Next close = the first close after a story against the close before it; official daily closes only, not a call, not advice.

The numbers

fiscal 2025, as filed with the SEC · 66-metric EOD snapshot via Databento

Market cap$216.3B

EV / True FCF27.6x

Revenue$29.4B +2.4%

True FCF (ex-SBC)$8.6B −8.2%

Rule of 4034.5%

ROIC20.3%

True FCF Yield4.0%

EPS, diluted$6.78 +1684.2%

Modern Valuation (EOD)

Market Cap$216.3B

Enterprise Value$236.5B

EV / True FCF27.63

EV / FCF25.01

EV / Gross Profit—

EV / EBIT23.60

EV / Sales8.03

P / E (GAAP)25.42

P / FCF22.88

P / Oper. CF21.59

P / Book9.57

Owner & Cash Yields

True FCF Yield4.0%

FCF Yield4.4%

Owner Earn. Yield3.4%

Earnings Yield3.9%

Shareholder Yield+2.3%

Buyback Yield0.9%

Dividend Yield1.89%

Dividend / sh$3.16

Payout Ratio47%

FCF / sh$7.62

EPS (diluted)$6.78

Compounder & Returns

Rule of 4034.5%

ROIC20.3%

Cash ROIC (CROIC)22.1%

GP / Assets—

ROE37.6%

ROA14.4%

Gross Margin—

Oper. Margin34.0%

Net Margin28.9%

FCF Margin32.1%

True FCF Margin29.1%

Quality & Dilution

Cash Conversion111%

Accrual Ratio−2.6%

SBC % of FCF9.5%

SBC % of Rev3.0%

Reinvest. Rate97%

Sales Growth Y/Y+2.4%

Sales 3Y CAGR+2.6%

EPS Growth Y/Y+1684.2%

FCF Growth Y/Y−8.2%

FCF 3Y CAGR+4.3%

Share Change Y/Y0.0%

Balance Sheet & Scale

Revenue (FY)$29.4B

Gross Profit (FY)—

Oper. Income (FY)$10.0B

GAAP Net Income$8.5B

True FCF (ex-SBC)$8.6B

Cash & Equiv$7.6B

Total Debt$27.7B

Net Cash (Debt)$-20.2B

Net Cash % MCap−9.3%

Debt / FCF (yrs)2.9y

Current Ratio1.551.24B sh

Price & Technicals (EOD)

Perf Week+1.18%

Perf Month+14.11%

Perf Quarter+25.79%

Perf Half Y+25.00%

Perf YTD+23.33%

SMA 20 Dist+5.19%$159.31

SMA 50 Dist+9.76%$152.68

SMA 100 Dist+17.21%$142.97

Window High−3.96%$174.48

Window Low+37.94%$121.48

RSI (14) · Vol61.337%v

Income Distribution & Cash Flow ConversionHow every dollar of GILD revenue flows through cost of goods, operating expenses, taxes, GAAP net income, and dilution-adjusted free cash flow

Where Every $100 of Revenue Goes (FY2025)

Cost of Revenue (COGS)$6.2B ($21.2 / $100)

R&D Reinvestment$9.1B ($30.9 / $100)

SG&A & Other OpEx$5.8B ($19.6 / $100)

Tax & Non-Operating$1.5B ($5.1 / $100)

Net Profit Kept$8.5B ($23.2 / $100)

Earnings Quality: GAAP Profit → True Owner Cash (FY2025)

GAAP Net Income$8.5B (28.9% margin)

Operating Cash Flow (OCF)$10.0B(34.0% of rev)

Less: Capital Expenditures−$563.0M(1.9% of rev)

Standard Free Cash Flow (FCF)$9.5B(32.1% margin)

Less: Stock-Based Comp (SBC)−$894.0M(9.5% of FCF)

True FCF (Owner Cash ex-SBC)$8.6B(29.1% of rev)

Revenue by fiscal year

Operating leverage — margins

GrossOperatingNet

Line Item (USD)	FY2021	FY2022	FY2023	FY2024	FY2025	YoY Δ	4Y CAGR
Income Statement
Revenue	$27.3B	$27.3B	$27.1B	$28.8B	$29.4B	+2.4%	+1.9%
Cost of Revenue (COGS)	$6.6B	$5.7B	$6.5B	$6.3B	$6.2B	−0.3%	−1.4%
Research & Development (R&D)	—	—	—	—	$9.1B	—	—
Selling, General & Admin (SG&A)	$5.2B	$5.7B	$6.1B	$6.1B	$5.8B	−5.2%	+2.4%
Operating Income (EBIT)	$9.9B	$7.3B	$7.6B	$1.7B	$10.0B	+503.0%	+0.3%
Interest Expense	$1.0B	$935.0M	$944.0M	$977.0M	$1.0B	+4.8%	+0.6%
Income Tax Expense	$2.1B	$1.2B	$1.2B	$211.0M	$1.3B	+509.5%	−11.3%
GAAP Net Income	$6.2B	$4.6B	$5.7B	$480.0M	$8.5B	+1672.9%	+8.1%
Diluted EPS	$4.93	$3.64	$4.50	$0.38	$6.78	+1684.2%	+8.3%
Diluted Shares	1.26B	1.26B	1.26B	1.25B	1.25B	+0.0%	−0.1%
Balance Sheet
Cash & Equivalents	$5.3B	$5.4B	$6.1B	$10.0B	$7.6B	−24.3%	+9.1%
Inventory	$1.6B	$1.5B	$1.8B	$1.7B	$1.8B	+3.7%	+2.3%
Total Current Assets	$14.8B	$14.4B	$16.1B	$19.2B	$18.3B	−4.3%	+5.6%
Total Assets	$68.0B	$63.2B	$62.1B	$59.0B	$59.0B	+0.0%	−3.5%
Total Current Liabilities	$11.6B	$11.2B	$11.3B	$12.0B	$11.8B	−1.6%	+0.4%
Total Debt (Short + Long Term)	$28.2B	$27.5B	$26.8B	$28.5B	$27.7B	−2.7%	−0.4%
Stockholders' Equity	$21.1B	$21.2B	$22.7B	$19.2B	$22.6B	+17.5%	+1.8%
Net Cash / (Net Debt)	$-22.9B	$-22.1B	$-20.7B	$-18.5B	$-20.2B	−8.9%	—
Invested Capital	$43.9B	$43.3B	$43.4B	$37.8B	$42.8B	+13.3%	−0.7%
Cash Flow & Capital Allocation
Operating Cash Flow (OCF)	$11.4B	$9.1B	$8.0B	$10.8B	$10.0B	−7.5%	−3.1%
Depreciation & Amortization (D&A)	$329.0M	$323.0M	$354.0M	$381.0M	$370.0M	−2.9%	+3.0%
Stock-Based Compensation (SBC)	$635.0M	$637.0M	$766.0M	$835.0M	$894.0M	+7.1%	+8.9%
Capital Expenditures (CapEx)	$579.0M	$728.0M	$585.0M	$523.0M	$563.0M	+7.6%	−0.7%
Free Cash Flow (FCF)	$10.8B	$8.3B	$7.4B	$10.3B	$9.5B	−8.2%	−3.3%
True FCF (ex-SBC Owner Cash)	$10.2B	$7.7B	$6.7B	$9.5B	$8.6B	−9.6%	−4.2%
Share Repurchases (Buybacks)	$546.0M	$1.4B	$1.0B	$1.1B	$1.9B	+67.1%	+37.0%
Dividends Paid	$3.6B	$3.7B	$3.8B	$3.9B	$4.0B	+2.2%	+2.7%

Fundamentals, income distribution and multi-year statements from SEC EDGAR filings (public domain). Valuation multiples, performance and technicals computed from Databento 1D EOD closes. For information only, not investment advice.

On the Wire

what GILD did at the next close after each story

No Wire story has named GILD yet.

What happened · big days

15 big days in a year, and what we hold on each

A big day is a close more than 3.33% from the one before, three times GILD’s median day (1.11%). On 10 of the 15, its peer group moved the same way at least half as far. We show what we hold. We never name a cause.

every other trading daya big day, numbered in the list below±3.33%Hover a bar for its day. Click a big day to open it.

Shaded: since our stories began, Jun 10. Tap a bar for its day.

#DayGILDWhat we hold that dayGroup (median of 4) · each

1 Nov 7, 2025−3.70%
Before our storiesgroup +0.4%, did not move with it
1Nov 7, 2025−3.70%
Before our stories
+0.4% did not move with itBIIB −0.8 · EXEL +0.0 · MRNA +0.9 · AMGN +1.5
2 Nov 11, 2025+3.73%
Before our storiesgroup +4.2%, moved with GILD
2Nov 11, 2025+3.73%
Before our stories
+4.2% moved with GILDMRNA +6.7 · AMGN +4.6 · EXEL +3.8 · BIIB +2.1
3 Jan 21, 2026+4.00%
Before our storiesgroup +4.1%, moved with GILD
3Jan 21, 2026+4.00%
Before our stories
+4.1% moved with GILDMRNA +15.8 · BIIB +4.4 · AMGN +3.8 · EXEL +2.4
4 Jan 23, 2026+3.65%
Before our storiesgroup −1.0%, did not move with it
4Jan 23, 2026+3.65%
Before our stories
−1.0% did not move with itEXEL −0.5 · AMGN −0.7 · BIIB −1.3 · MRNA −6.1
5 Feb 11, 2026+5.82%
Resultsgroup +0.2%, did not move with it
5Feb 11, 2026+5.82%
ResultsFirst close after the Feb 10 results filing
+0.2% did not move with itBIIB +1.2 · AMGN +0.5 · EXEL −0.1 · MRNA −3.5
6 Feb 27, 2026+3.60%
Before our storiesgroup +2.2%, moved with GILD
6Feb 27, 2026+3.60%
Before our stories
+2.2% moved with GILDMRNA +3.6 · AMGN +2.3 · BIIB +2.0 · EXEL −0.5
7 Jun 11, 2026+3.61%
Nothing on GILDgroup +3.9%, moved with GILD
7Jun 11, 2026+3.61%
Nothing on GILDNo GILD story, brief or results filing in our record that day
+3.9% moved with GILDMRNA +7.9 · AMGN +4.8 · BIIB +2.9 · EXEL +1.8
8 Jul 2, 2026+4.21%
Nothing on GILDgroup +3.5%, moved with GILD
8Jul 2, 2026+4.21%
Nothing on GILDNo GILD story, brief or results filing in our record that day
+3.5% moved with GILDMRNA +10.0 · AMGN +3.5 · EXEL +3.5 · BIIB +3.0
9 Jul 7, 2026+5.21%
Nothing on GILDgroup −0.4%, did not move with it
9Jul 7, 2026+5.21%
Nothing on GILDNo GILD story, brief or results filing in our record that day
−0.4% did not move with itEXEL +2.8 · AMGN +0.5 · BIIB −1.3 · MRNA −2.5
10 Jul 10, 2026−3.72%
Nothing on GILDgroup −0.6%, did not move with it
10Jul 10, 2026−3.72%
Nothing on GILDNo GILD story, brief or results filing in our record that day
−0.6% did not move with itMRNA −10.8 · EXEL −1.1 · AMGN −0.1 · BIIB +0.1
11 Jul 16, 2026+3.49%
Nothing on GILDgroup +2.0%, moved with GILD
11Jul 16, 2026+3.49%
Nothing on GILDNo GILD story, brief or results filing in our record that day
+2.0% moved with GILDBIIB +5.9 · AMGN +3.7 · EXEL +0.2 · MRNA −7.5
12 Oct 14, 2026+3.80%
Nothing on GILDgroup +2.9%, moved with GILD
12Oct 14, 2026+3.80%
Nothing on GILDNo GILD story, brief or results filing in our record that day
+2.9% moved with GILDMRNA +4.7 · AMGN +3.2 · EXEL +2.5 · BIIB +1.7
13 Oct 29, 2026+4.03%
Nothing on GILDgroup +2.1%, moved with GILD
13Oct 29, 2026+4.03%
Nothing on GILDNo GILD story, brief or results filing in our record that day
+2.1% moved with GILDMRNA +4.0 · BIIB +2.3 · AMGN +2.0 · EXEL −0.1
14 Nov 4, 2026+4.19%
Nothing on GILDgroup +3.0%, moved with GILD
14Nov 4, 2026+4.19%
Nothing on GILDNo GILD story, brief or results filing in our record that day
+3.0% moved with GILDMRNA +13.1 · AMGN +3.7 · BIIB +2.2 · EXEL +0.6
15 Nov 5, 2026−3.96%
Nothing on GILDgroup −4.8%, moved with GILD
15Nov 5, 2026−3.96%
Nothing on GILDNo GILD story, brief or results filing in our record that day
−4.8% moved with GILDMRNA −6.5 · EXEL −5.5 · BIIB −4.1 · AMGN −3.8

A story on the same day is not a cause, and a group move is not proof either. Group: the median of AMGN, MRNA, BIIB and EXEL that day, the largest companies in GILD’s SEC industry; “moved with GILD” means the same direction and at least half the size.

What’s next · results

Before the next report: what the first day after the last four did

Six trading days after each results filing (SEC 8-K, Item 2.02). GILD reports after the close, so day 1 is the next close. 3 of 4 times, day 6 ended on the same side as day 1.

Reported Oct 30, 2025

day 1+1.14%day 6+0.34%

Reported Feb 10, 2026

day 1+5.82%day 6+2.64%

Reported May 7, 2026

day 1−2.04%day 6−3.34%

Reported Aug 4, 2026

day 1−2.58%day 6+0.46%

Next report: expected late January to early FebruaryEstimated from the dates of its last four results filings. Not announced. Since the Oct 29 report: +1.18%. Four reports is a small sample.

Every report since 2023 →

Each line is GILD’s close against its close before the filing, on licensed end-of-day closes. What happened after each report, not a forecast; a move on the day is not a cause.

Same industry

GILD against four biotech peers, a year at 100

GILD is up 41.0% in a year. Moderna is up 9.8 times, Exelixis is up 68.4%, Biogen 56.9% and Amgen 43.8%. All four did more. Weekly closes, Nov 7, 2025 = 100, on a log scale so a 9.8-fold rise and a 41.0% rise both read honestly.

Share this chart

GILD +41.0%. Moderna ×9.8, Exelixis +68.4%, Biogen +56.9%, Amgen +43.8%. Weekly closes, Nov 7, 2025 = 100, log scale.

Share this chart

End-of-day closes (Databento EOD), the last close of each week. The four peers are the largest US-listed companies by market value in GILD’s SEC industry (Biological Products, (No Diagnostic Substances)) with a year of closes. It shows what the closes did; a move here is not a cause, a forecast or a call.

The Wire at 7 AM ET, free. Top stories with a bull and a bear case on each, every morning. No account needed.

AMGN	Amgen	$258.7B	−3.80%
MRNA	Moderna	$103.2B	−6.55%
BIIB	Biogen	$37.6B	−4.14%
EXEL	Exelixis	$18.0B	−5.55%
NBIX	Neurocrine Biosciences	$16.9B	−3.79%
HALO	Halozyme Therapeutics	$14.8B	−5.66%
TECH	BIO-TECHNE	$11.4B	−0.10%
KYMR	Kymera Therapeutics	$11.3B	−5.97%